The present technology is directed generally to systems and methods for positioning implanted devices in a patient.
Neurological stimulators have been developed to treat pain, movement disorders, functional disorders, spasticity, cancer, cardiac disorders, and various other medical conditions. Implantable neurological stimulation systems generally have an implantable pulse generator and one or more leads that deliver electrical pulses to neurological tissue or muscle tissue. For example, several neurological stimulation systems for spinal cord stimulation (SCS) have cylindrical leads that include a lead body with a circular cross-sectional shape and multiple conductive rings spaced apart from each other at the distal end of the lead body. The conductive rings operate as individual electrodes and the SCS leads are typically implanted either surgically or percutaneously through a large needle inserted into the epidural space, with or without the assistance of a stylet.
Once implanted, the pulse generator applies electrical pulses to the electrodes, which in turn modify the function of the patient's nervous system, such as by altering the patient's responsiveness to sensory stimuli and/or altering the patient's motor-circuit output. During pain treatment, the pulse generator applies electrical pulses to the electrodes, which in turn can generate sensations that mask or otherwise alter the patient's sensation of pain. For example, in many cases, patients report a tingling or paresthesia that is perceived as more pleasant and/or less uncomfortable than the underlying pain sensation. In other cases, the patients can report pain relief without paresthesia or other sensations.
In any of the foregoing systems, it is important for the practitioner to accurately position the stimulator in order to provide effective therapy. One approach to accurately positioning the stimulator is to implant the stimulator in a surgical procedure so that the practitioner has a clear visual access to the implantation site. However, many patients and practitioners wish to avoid the invasiveness and associated likelihood for complications typical of a surgical procedure. Accordingly, many patients and practitioners prefer a less invasive (e.g., percutaneous) implantation technique. With a percutaneous approach, the practitioner typically is unable to see exactly where the device is positioned because the device is beneath the patient's skin and in most SCS cases, within the patient's spinal column. In addition, the process typically requires the patient to provide feedback to the practitioner based on that patient's sensations. Accordingly, the industry has developed a variety of techniques for visualizing medical devices and anatomical features below the patient's skin as the device is implanted. Such techniques include fluoroscopy, which is commonly used to aid the practitioner when implanting SCS leads. However, a drawback with fluoroscopy is that it results in added expense to the SCS implantation procedure, it may be cumbersome to implement, it limits the implantation procedure to sites with fluoroscopy equipment, and it exposes the patient to unwanted x-ray radiation. Accordingly, there remains a need in the art for improved visualization techniques that can be used to implant patient devices with greater ease, accuracy, and lower cost.
The present technology is directed generally to systems and methods for positioning implanted devices in a patient. In at least some contexts, the systems and methods are used to implant leads proximate to the patient's spinal cord to deliver high frequency signals that modulate neural activity at the patient's spine, in particular embodiments, to address chronic pain. In other embodiments, however, the systems and associated methods can have different configurations, components, and/or procedures. Still other embodiments may eliminate particular components or procedures. A person of ordinary skill in the relevant art, therefore, will understand that the present technology may include other embodiments with additional elements, and/or may include other embodiments without several of the features shown and described below with reference to
Several aspects of the technology are embodied in computing devices, e.g., programmed pulse generators, controllers and/or other devices. The computing devices on which the described technology can be implemented may include one or more central processing units, memory, input devices (e.g., input ports), output devices (e.g., display devices), storage devices, and network devices (e.g., network interfaces). The memory and storage devices are computer-readable media that may store instructions that implement the technology. In many embodiments, the computer readable media are tangible media. In other embodiments, the data structures and message structures may be stored or transmitted via an intangible data transmission medium, such as a signal on a communications link. Various suitable communications links may be used, including but not limited to a local area network and/or a wide-area network.
In a representative example, the signal delivery system 110 includes a signal delivery device 111 that carries features for delivering therapy to the patient 190 after implantation. The pulse generator 121 can be connected directly to the signal delivery device 111, or it can be coupled to the signal delivery device 111 via a signal link 113 (e.g., an extension). In a further representative embodiment, the signal delivery device 111 can include an elongated lead or lead body 112. As used herein, the terms “lead” and “lead body” include any of a number of suitable substrates and/or support members that carry devices for providing therapy signals to the patient 190. For example, the lead 112 can include one or more electrodes or electrical contacts that direct electrical signals into the patient's tissue, such as to provide for patient relief. In other embodiments, the signal delivery device 111 can include structures other than a lead body (e.g., a paddle) that also direct electrical signals and/or other types of signals to the patient 190.
The pulse generator 121 can transmit signals (e.g., electrical signals) to the signal delivery device 111 that up-regulate (e.g., stimulate or excite) and/or down-regulate (e.g., block or suppress) target nerves. As used herein, and unless otherwise noted, the terms “modulate” and “modulation” refer generally to signals that have either type of the foregoing effects on the target nerves. The pulse generator 121 can include a machine-readable (e.g., computer-readable) medium containing instructions for generating and transmitting suitable therapy signals. The pulse generator 121 and/or other elements of the system 100 can include one or more processors 122, memories 123 and/or input/output devices. Accordingly, the process of providing modulation signals, providing guidance information for locating the signal delivery device 111, and/or executing other associated functions can be performed by computer-executable instructions contained by computer-readable media located at the pulse generator 121 and/or other system components. The pulse generator 121 can include multiple portions, elements, and/or subsystems (e.g., for directing signals in accordance with multiple signal delivery parameters), carried in a single housing, as shown in
In some embodiments, the pulse generator 121 can obtain power to generate the therapy signals from an external power source 118. The external power source 118 can transmit power to the implanted pulse generator 121 using electromagnetic induction (e.g., RF signals). For example, the external power source 118 can include an external coil 119 that communicates with a corresponding internal coil (not shown) within the implantable pulse generator 121. The external power source 118 can be portable for ease of use.
During at least some procedures, an external programmer 120 (e.g., a trial modulator) can be coupled to the signal delivery device 111 during an initial procedure, prior to implanting the pulse generator 121. For example, a practitioner (e.g., a physician and/or a company representative) can use the external programmer 120 to vary the modulation parameters provided to the signal delivery device 111 in real time, and select optimal or particularly efficacious parameters. These parameters can include the location from which the electrical signals are emitted, as well as the characteristics of the electrical signals provided to the signal delivery device 111. In a typical process, the practitioner uses a cable assembly 114 to temporarily connect the external programmer 120 to the signal delivery device 111. The practitioner can test the efficacy of the signal delivery device 111 in an initial position. The practitioner can then disconnect the cable assembly 114 (e.g., at a connector 117), reposition the signal delivery device 111, and reapply the electrical modulation. This process can be performed iteratively until the practitioner obtains the desired position for the signal delivery device 111. Optionally, the practitioner may move the partially implanted signal delivery element 111 without disconnecting the cable assembly 114.
After a trial period with the external programmer 120, the practitioner can implant the implantable pulse generator 121 within the patient 190 for longer term treatment. The signal delivery parameters provided by the pulse generator 121 can still be updated after the pulse generator 121 is implanted, via a wireless physician's programmer 125 (e.g., a physician's remote) and/or a wireless patient programmer 124 (e.g., a patient remote). Generally, the patient 190 has control over fewer parameters than does the practitioner.
The spinal cord 191 is situated within a vertebral foramen 188, between a ventrally located ventral body 196 and a dorsally located transverse process 198 and spinous process 197. Arrows V and D identify the ventral and dorsal directions, respectively. The spinal cord 191 itself is located within the dura mater 199, which also surrounds portions of the nerves exiting the spinal cord 191, including the ventral roots 192, dorsal roots 193 and dorsal root ganglia 194. In one embodiment, a single first signal delivery device 111a is positioned within the vertebral foramen 188, at or approximately at the spinal cord midline 189. In another embodiment, two second signal delivery devices 111b are positioned just off the spinal cord midline 189 (e.g., about 1 mm. offset) in opposing lateral directions so that the two signal delivery devices 111b are spaced apart from each other by about 2 mm. In still further embodiments, a single signal delivery device or pairs of signal delivery devices can be positioned at other locations, e.g., at the dorsal root entry zone as shown by a third signal delivery device 111c, or at the dorsal root ganglia 194, as shown by a fourth signal delivery device 111d.
In any of the foregoing embodiments, it is important that the signal delivery device 111 be placed at a target location that is expected (e.g., by a practitioner) to produce efficacious results in the patient when activated. The following disclosure describes techniques and systems for improving the level of accuracy with which the devices are positioned.
The lead 112 and/or other portions of the overall system 100 can include features that guide the practitioner when positioning the lead 112 at a target location. For example, the signal transmission system 130 can be carried by the lead 112 and/or the implanting tool 160, and can communicate with the signal detector system 140 located outside the patient's body. In a particular embodiment, the signal transmission system 130 includes one or more signal transmission devices 131. For purposes of illustration, several different signal transmission devices 131 are shown together in
An advantageous feature of the first signal transmission device 131a is that its independence of therapy contacts 126 frees it from being limited by the particular geometry and arrangement of the therapy contacts 126, which are typically sized, configured and arranged to provide optimal or highly effective and efficient therapy (e.g., modulation) signals. Instead, the first signal transmission device 131a can be tailored to provide effective and efficient first locator signals 132a, e.g., in cases where the locator signals differ significantly from the therapy/modulation signals. Conversely, an advantage of combining the functions of the second signal transmission device 131b with one of the therapy contacts 126 is that it reduces the need for an additional element in the overall patient system 100. An advantage of the third signal transmission device 131c is that it can be removed from the patient's body when it is no longer needed for locating the lead 112. Although the configuration and individual features of the three signal transmission devices 131a, 131b, and 131c in the embodiment of
The locator signals 132 transmitted by the signal transmission device 131 can have any of a variety of characteristics suitable for conveying location information wirelessly through the patient's skin 187 to the signal detector device 141. For example, in a particular embodiment, the locator signal 132 can include a radio frequency (RF) signal having a frequency in the range of from about 10 kHz to about 30 GHz. In other embodiments, the frequency of the locator signal 132 is outside the foregoing range. In still further embodiments, the signal transmission device 131 can be a magnetic device (e.g., a permanent magnet and/or an electromagnet) and can accordingly transmit locator signals 132 by virtue of magnetic fields, which are detected by the signal detector device 141. Accordingly, the term “locator signal” as used herein includes a wide variety of electromagnetic fields and transmissions that can be received or otherwise detected by an appropriate detector device 141. The signal can be generally constant, as in the case of a magnetic field produced by a permanent magnet, or varying, as in the case of an RF signal. In still a further embodiment, the locator signal 132 can be an acoustic signal (e.g., ultrasound) that is transmitted by the signal transmission device 131 and received by the signal detector device 141. In yet another aspect of this embodiment, the locator signal can actually be emitted from a location external to the patient's body, and the signal detector device 141 can receive or detect an echo or return signal, as indicated by fourth (two-way) locator signals 132d. Accordingly, unless otherwise indicated, the term “signal transmission device” includes devices that emit (e.g., actively generate) signals, and devices that reflect signals, with both types of signals selected to be detected by the signal detector device 141.
When the signal includes a reflected ultrasound signal, the signal emitter can be co-housed with the signal detector 141 to simplify use. The signal delivery device 111 and/or the implanting tool 160 can be constructed from materials specifically selected to be highly reflective to ultrasound signals and/or surface treatments to optimize ultrasound reflectivity. Materials having densities different than the densities of the adjacent tissue (which has a significant water content) typically have a higher acoustic impedance and accordingly generate reflections that can be readily distinguished from those produced by the adjacent tissue. Such materials can include polymers such as polyethylene or polyurethane. In other embodiments, the materials can include compositions having higher densities and/or materials that are also radiopaque, so that they can be used with a fluoroscopic detection technique and/or an ultrasonic detection technique. Suitable materials include platinum, iridium, tantalum, titanium and/or alloys of the foregoing materials. The materials can be applied to one or more of several elements of the signal delivery system 110, including the therapy contacts 126, the stylet stop 128, and/or the end of the stylet shaft 162, which can have a ball shape (e.g., a welded ball) to inhibit penetration into the distal end of the lead 112. In other embodiments, a radiopaque and acoustically reflective ink or other coating can be applied to any of the foregoing elements and/or to the outer surface of the stylet shaft 162 and/or to the outer surface of the lead 112. Suitable materials include radiopaque inks available from CJ Medical of Norton, Mass., and sputtered tantalum available from Isoflex Biomed of Rochester, N.Y.
In any of the foregoing embodiments, locator signals are generally transmitted (e.g., actively or by reflection) from the signal transmission device 131 to the signal detector device 141. As discussed above, signals can travel in both directions when the detected signal is a reflected signal. In other embodiments, the signal detector device 141 can transmit additional signals to the signal transmission device 131, e.g., to power the signal transmission device 131, and/or to query the signal transmission device 131 for additional information.
In at least some embodiments, the signal detector system 140 can include a single detector device 141, as shown in
As the practitioner inserts the signal delivery system 110 along the patient's spine 184, the signal delivery system 110 (e.g., the signal delivery device 111 and associated implanting tool 160) can move in several directions. For example, as shown in
Because the detector elements 143 shown in the array 142 are positioned in a plane (e.g., a generally flat plane) that contains the axial and lateral axes 101, 102, the detector elements 143 tend to be most sensitive to the location of the signal delivery system 110 in these generally orthogonal directions. The detector elements 143 may not be as sensitive to motion along the ventral/dorsal axis 103, and/or motion of the signal delivery system 110 wrapping around the spinal cord. Accordingly, the overall system 100 can include other features that may supplement the information received from the detector elements 143. In a particular embodiment, the overall system 100 can include an insertion tracker 150 (shown schematically in
In operation, the information received by the detector elements 143 can be used to estimate a length of the signal delivery device 111 projected into the plane of the array 142. This estimated length can be compared to the length indicated by the insertion tracker 150, either by the practitioner, or in an automated manner by the overall system 100, based on the output signal 153. If the location of the signal delivery device 111 as indicated by the detector elements 143 corresponds to (e.g., is identical or nearly identical to) the inserted length of the signal delivery device 111 identified by the insertion tracker 150, then the signal delivery device 111 has not likely deviated significantly from a plane located just above the spinal cord. Alternatively, if the detector elements 143 indicate that the signal delivery device 111 is not progressing (or progressing slowly) in the lateral or axial directions, but the insertion tracker 150 indicates that the signal delivery device 111 is in fact progressing (or progressing quickly), this can indicate to the practitioner that the signal delivery device 111 is traveling out of the plane of the array 142, e.g., either penetrating toward or into the spinal cord, or wrapping around the spinal cord. Further aspects of this operation are described later with reference to
As shown in
In an embodiment shown in
The foregoing information received from the detector elements 143 can be combined with information received via the insertion tracker output 153 to indicate when the signal delivery device 111 (
In a particular embodiment, the intrathecal penetration detector 180 includes a power source 181 that applies a detection signal to a detection circuit 183. The detection circuit 183 includes patient tissue, and can further include one or more of the therapy contacts 126 in contact with the patient tissue. Using the therapy contacts 126 as part of the impedance circuit 183 reduces the need for adding additional features to the signal delivery device 111; nevertheless, in another embodiment, the signal delivery device 111 can carry contacts that are dedicated to impedance detection. In a particular embodiment, the detection circuit 183 can include two selected therapy contacts 126 and the patient tissue located between the two therapy contacts 126. In another embodiment, the detection circuit 183 can include a single therapy contact 126 and ground (e.g., a patient ground pad).
The intrathecal penetration detector 180 further includes an impedance detector 182 in the detection circuit 183 that identifies the impedance of the circuit 183. The impedance detector 182 can be connected to the processor 148, memory 149, and display device 170a described above with reference to
It is generally expected that the impedance of a circuit that includes two therapy contacts 126, as shown schematically in
In a particular embodiment, the practitioner can select from any of the therapy contacts 126 to be included in the impedance detection circuit 183. In at least some embodiments, the practitioner may wish to include the distal-most therapy contact (e.g., at the distal tip of the signal delivery device 111) in the detection circuit 183 to provide an early indication that the signal delivery device 111 has penetrated the dura 199. If the signal delivery device 111 does not include a therapy contact 126 at the tip, a special-purpose contact can be added to the signal delivery device 111, or the practitioner can use the therapy contact 126 closest to the tip. In other embodiments, the practitioner may wish to include one or more of the other therapy contacts 126 in the circuit, for example, to identify the extent and/or rate of a cerebral spinal fluid leak, and/or for other diagnostic purposes.
As discussed above, the information received from the impedance detector 182 can be processed to indicate to the practitioner whether or not the dura 199 has been penetrated. The information can be provided in a fairly straightforward manner, e.g., by indicating either no intrathecal penetration or intrathecal penetration, optionally with an intermediate indication of likely CSF leakage. In other embodiments, the intrathecal penetration detector 180 can provide more sophisticated information. For example, the intrathecal penetration detector 180 can employ a multiplex arrangement or other suitable signal processing arrangement to scan over the therapy contacts 126 and identify issues or insipient issues associated with any of the contacts 126. The intrathecal penetration detector 180 can track a rate at which a drop in impedance passes along the signal delivery device 111 (e.g., as detected by multiple therapy contacts 126) to provide the practitioner with an indication of the rate at which CSF is leaking from the dura 199. In other embodiments, the intrathecal penetration detector 180 can include other arrangements. For example, the intrathecal penetration detector 180 can indicate which contacts(s) 126 have lower than expected associated impedance. In a particular example, the tip of the signal delivery device may penetrate the dura 199 by breaking the continuity of the dura 199 without actually proceeding into the subdural space. Leaking CSF may then be indicated by low impedances at proximal therapy contacts 126 as they pass by the break in the dura 199, and/or as CSF flows in a proximal direction, but a normal impedance (at least for a period of time) at the distalmost therapy contact 126.
The foregoing process can be performed without the use of fluoroscopy (process portion 703a). For example, in particular embodiments, the practitioner can use electromagnetic techniques (e.g., RF or magnetic techniques) or ultrasound techniques to accurately implant the signal delivery device on a consistent, repeatable basis over multiple patients (e.g., a patient population numbering in the tens or hundreds or more). In further particular embodiments, the accuracy of this method can be better than ±5 mm., e.g., ±2 mm. or ±1 mm., depending on factors that include, but are not limited to, the sensitivity of the signal detector or signal detector elements, the unidirectionality of the signal transmitters, and the spacing between signal detector elements. In any of these embodiments, the ability to locate the signal delivery device within the foregoing ranges without the use of fluoroscopy can simplify the implanting process, and can reduce the patient's exposure to x-ray radiation. In addition, fluoroscopy devices can be cumbersome and, due to the protective gear worn by the practitioner, can interfere with the practitioners freedom of movement. Still further, fluoroscopy equipment is generally expensive and not generally available in remote and/or developing parts of the world. The current technology can reduce or eliminate the dependence on fluoroscopy for accurate device placement which can in turn allow the device and associated therapy to be used in a larger number of treatment centers (i.e., those without fluoroscopic equipment) and a concomitant potentially greater number of patients in need of such therapy.
Optionally, the process 700a can be performed with less or no patient feedback (process portion 704a). For example, the increased accuracy with which the signal delivery device is implanted in the first instance can reduce the number of subsequent iterations the practitioner and patient engage in to identify an effective location for the signal delivery device and associated therapy contacts. Such iterations can include moving the signal delivery device and/or selecting different active contacts on the signal delivery device.
Once the signal delivery device is implanted, it can be activated to modulate neural activity at the spinal cord (process portion 705a). In a particular embodiment, the therapy includes RF signals delivered to the patient's spinal cord at a frequency of from about 3 kHz to about 50 kHz to address patient pain. Further details of suitable signal delivery parameters are included in pending U.S. patent application Ser. No. 12/765,747, filed on Apr. 22, 2010 and incorporated herein by reference in its entirety. In other embodiments, the signal delivery device can provide signals in accordance with other signal delivery parameters to treat the same or other patient indications, at the same or other implantation sites.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. For example, in other embodiments, the foregoing systems and methods can be used to locate devices other than spinal cord implants. In a particular embodiment, the intrathecal detection device and methodology described above can be applied to other areas of the patient's body that are surrounded by the dura and contain cerebral spinal fluid, for example, the brain. In still further embodiments, these devices and methodologies can be applied to implantable patient devices other than neural modulators (e.g., other elements configured for patient implantation, with therapy contacts in at least some cases). The implanting tools described above can have configurations other than a stylet (e.g., a catheter) in other embodiments. The locator signal emitters and/detectors can be omnidirectional in certain embodiments or can be unidirectional in other embodiments. In certain embodiments, phase shift and/or phased array techniques can be implemented to enhance system efficacy. The signal delivery system can include one transmission device in certain embodiments, and more than one transmission device in other embodiments.
Certain aspects of the technology described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, the display 170a described above with reference to
This application is a continuation of U.S. patent application Ser. No. 15/148,987, filed May 6, 2016, which is a continuation of U.S. patent application Ser. No. 14/598,114, now issued as U.S. Pat. No. 9,345,891, filed Jan. 15, 2015, which is a continuation of U.S. patent application Ser. No. 12/895,403, now issued as U.S. Pat. No. 8,965,482, filed Sep. 30, 2010, which are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3195540 | Waller et al. | Jul 1965 | A |
3724467 | Avery et al. | Apr 1973 | A |
3774618 | Avery | Nov 1973 | A |
3796221 | Hagfors | Mar 1974 | A |
4096866 | Fischell | Jun 1978 | A |
4136703 | Wittkampf | Jan 1979 | A |
4141365 | Fischell et al. | Feb 1979 | A |
4282886 | King | Aug 1981 | A |
4328813 | Ray | May 1982 | A |
4355224 | Mesick et al. | Oct 1982 | A |
4422917 | Hayfield | Dec 1983 | A |
4432377 | Dickhudt | Feb 1984 | A |
4462401 | Burgio | Jul 1984 | A |
4462402 | Burgio et al. | Jul 1984 | A |
4465079 | Dickhudt | Aug 1984 | A |
4498482 | Williams | Feb 1985 | A |
4515168 | Chester et al. | May 1985 | A |
4538624 | Tarjan | Sep 1985 | A |
4573448 | Kambin | Mar 1986 | A |
4573481 | Bullara | Mar 1986 | A |
4579120 | MacGregor | Apr 1986 | A |
4603696 | Cross, Jr. et al. | Aug 1986 | A |
4658835 | Pohndorf | Apr 1987 | A |
4683895 | Pohndorf | Aug 1987 | A |
4721551 | Byers et al. | Jan 1988 | A |
4744370 | Harris | May 1988 | A |
4744371 | Harris | May 1988 | A |
4764132 | Stutz, Jr. | Aug 1988 | A |
4796642 | Harris | Jan 1989 | A |
4830776 | Thompson | May 1989 | A |
4919653 | Martinez et al. | Apr 1990 | A |
4920979 | Bullara | May 1990 | A |
4926878 | Snedeker | May 1990 | A |
4934383 | Glumac | Jun 1990 | A |
4940065 | Tanagho et al. | Jul 1990 | A |
4961434 | Stypulkowski | Oct 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
5000194 | Van den Honert et al. | Mar 1991 | A |
5007902 | Witt | Apr 1991 | A |
5036862 | Pohndorf | Aug 1991 | A |
5042486 | Pfeiler et al. | Aug 1991 | A |
5046511 | Maurer et al. | Sep 1991 | A |
5072458 | Suzuki | Dec 1991 | A |
5078140 | Kwoh | Jan 1992 | A |
5159926 | Ljungstroem | Nov 1992 | A |
5205297 | Montecalvo et al. | Apr 1993 | A |
5211165 | Dumoulin et al. | May 1993 | A |
5257636 | White | Nov 1993 | A |
5265608 | Lee et al. | Nov 1993 | A |
5273053 | Pohndorf | Dec 1993 | A |
5306236 | Blumenfeld et al. | Apr 1994 | A |
5314458 | Najafi et al. | May 1994 | A |
5325873 | Hirschi et al. | Jul 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5351687 | Kroll et al. | Oct 1994 | A |
5351697 | Cheney et al. | Oct 1994 | A |
5360441 | Otten | Nov 1994 | A |
5366489 | Burgio et al. | Nov 1994 | A |
5375596 | Twiss et al. | Dec 1994 | A |
5425367 | Shapiro et al. | Jun 1995 | A |
5458629 | Baudino et al. | Oct 1995 | A |
5458631 | Xavier | Oct 1995 | A |
5464446 | Dreessen et al. | Nov 1995 | A |
5496363 | Burgio et al. | Mar 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5527358 | Mehmanesh et al. | Jun 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5562722 | Racz et al. | Oct 1996 | A |
5578074 | Mirigian | Nov 1996 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5669882 | Pyles | Sep 1997 | A |
5727553 | Saad | Mar 1998 | A |
5728148 | Bostrom et al. | Mar 1998 | A |
5730628 | Hawkins | Mar 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5759471 | Malewicz | Jun 1998 | A |
5760341 | Laske et al. | Jun 1998 | A |
5769877 | Barreras, Sr. | Jun 1998 | A |
5843148 | Gijsbers | Dec 1998 | A |
5846226 | Urmey | Dec 1998 | A |
5848126 | Fujita et al. | Dec 1998 | A |
5865843 | Baudino | Feb 1999 | A |
5871487 | Warner et al. | Feb 1999 | A |
5902236 | Iversen | May 1999 | A |
5927277 | Baudino et al. | Jul 1999 | A |
5935159 | Cross, Jr. et al. | Aug 1999 | A |
5957965 | Moumane et al. | Sep 1999 | A |
5957968 | Belden et al. | Sep 1999 | A |
5983126 | Wittkampf | Nov 1999 | A |
6052623 | Fenner et al. | Apr 2000 | A |
6055456 | Gerber | Apr 2000 | A |
6066165 | Racz | May 2000 | A |
6078839 | Carson | Jun 2000 | A |
6104960 | Duysens | Aug 2000 | A |
6106460 | Panescu et al. | Aug 2000 | A |
6125291 | Miesel et al. | Sep 2000 | A |
6129742 | Wu et al. | Oct 2000 | A |
6134459 | Roberts et al. | Oct 2000 | A |
6134477 | Knuteson | Oct 2000 | A |
6144866 | Miesel et al. | Nov 2000 | A |
6154678 | Lauro | Nov 2000 | A |
6163727 | Errico | Dec 2000 | A |
6178357 | Gliner et al. | Jan 2001 | B1 |
6185463 | Baudino | Feb 2001 | B1 |
6192279 | Barreras, Sr. et al. | Feb 2001 | B1 |
6198952 | Miesel | Mar 2001 | B1 |
6198963 | Haim et al. | Mar 2001 | B1 |
6205356 | Holcomb | Mar 2001 | B1 |
6210417 | Baudino et al. | Apr 2001 | B1 |
6214016 | Williams et al. | Apr 2001 | B1 |
6216045 | Black et al. | Apr 2001 | B1 |
6249965 | Bullara et al. | Jun 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6263230 | Haynor et al. | Jul 2001 | B1 |
6292702 | King et al. | Sep 2001 | B1 |
6298265 | Burgio | Oct 2001 | B1 |
6304785 | McCreery et al. | Oct 2001 | B1 |
6308103 | Gielen | Oct 2001 | B1 |
6309401 | Redko et al. | Oct 2001 | B1 |
6321104 | Gielen et al. | Nov 2001 | B1 |
6321123 | Morris et al. | Nov 2001 | B1 |
6366815 | Haugland et al. | Apr 2002 | B1 |
6393327 | Scribner | May 2002 | B1 |
6397108 | Camps et al. | May 2002 | B1 |
6442435 | King et al. | Aug 2002 | B2 |
6445955 | Michelson et al. | Sep 2002 | B1 |
6456866 | Tyler et al. | Sep 2002 | B1 |
6464682 | Snoke | Oct 2002 | B1 |
6473653 | Schallhorn et al. | Oct 2002 | B1 |
6474341 | Hunter et al. | Nov 2002 | B1 |
6477427 | Stolz et al. | Nov 2002 | B1 |
6493590 | Wessman et al. | Dec 2002 | B1 |
6493592 | Leonard et al. | Dec 2002 | B1 |
6516226 | Bishay et al. | Feb 2003 | B1 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6516807 | Panescu et al. | Feb 2003 | B1 |
6522927 | Bishay et al. | Feb 2003 | B1 |
6522932 | Kuzma et al. | Feb 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6546293 | Errico et al. | Apr 2003 | B2 |
6549797 | Leonard et al. | Apr 2003 | B1 |
6549810 | Leonard et al. | Apr 2003 | B1 |
6549812 | Smits | Apr 2003 | B1 |
6556869 | Leonard et al. | Apr 2003 | B1 |
6556873 | Smits | Apr 2003 | B1 |
6560491 | Leonard et al. | May 2003 | B1 |
6587733 | Cross, Jr. et al. | Jul 2003 | B1 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6609029 | Mann et al. | Aug 2003 | B1 |
6622051 | Bishay et al. | Sep 2003 | B1 |
6714822 | King et al. | Mar 2004 | B2 |
6718211 | Smits | Apr 2004 | B2 |
6721604 | Robinson et al. | Apr 2004 | B1 |
6733500 | Kelley et al. | May 2004 | B2 |
6741892 | Meadows et al. | May 2004 | B1 |
6741893 | Smits | May 2004 | B2 |
6754539 | Erickson et al. | Jun 2004 | B1 |
6785571 | Glossop et al. | Aug 2004 | B2 |
6847845 | Belden | Jan 2005 | B2 |
6875571 | Crabtree et al. | Apr 2005 | B2 |
6895276 | Kast et al. | May 2005 | B2 |
6895283 | Erickson et al. | May 2005 | B2 |
6907299 | Han | Jun 2005 | B2 |
6909918 | Stypulkowski | Jun 2005 | B2 |
6934589 | Sundquist et al. | Aug 2005 | B2 |
6970747 | Kokones et al. | Nov 2005 | B2 |
6980863 | Van Venrooij et al. | Dec 2005 | B2 |
6981314 | Black et al. | Jan 2006 | B2 |
6993384 | Bradley et al. | Jan 2006 | B2 |
6999820 | Jordan | Feb 2006 | B2 |
7010856 | Suda et al. | Mar 2006 | B2 |
7035690 | Goetz | Apr 2006 | B2 |
7047082 | Schrom et al. | May 2006 | B1 |
7051419 | Schrom et al. | May 2006 | B2 |
7072719 | Vinup et al. | Jul 2006 | B2 |
7107104 | Keravel et al. | Sep 2006 | B2 |
7110827 | Sage et al. | Sep 2006 | B2 |
7130696 | Carter et al. | Oct 2006 | B2 |
7133722 | Hansen et al. | Nov 2006 | B2 |
7142919 | Hine et al. | Nov 2006 | B2 |
7142925 | Bhadra et al. | Nov 2006 | B1 |
7146222 | Boling | Dec 2006 | B2 |
7146224 | King | Dec 2006 | B2 |
7149585 | Wessman et al. | Dec 2006 | B2 |
7164951 | Ries et al. | Jan 2007 | B2 |
7174219 | Wahlstrand et al. | Feb 2007 | B2 |
7184838 | Cross, Jr. | Feb 2007 | B2 |
7184840 | Stolz et al. | Feb 2007 | B2 |
7187981 | Tanaka | Mar 2007 | B2 |
7206642 | Pardo et al. | Apr 2007 | B2 |
7211103 | Greenberg et al. | May 2007 | B2 |
7212867 | Van Venrooij et al. | May 2007 | B2 |
7236834 | Christopherson et al. | Jun 2007 | B2 |
7244150 | Brase et al. | Jul 2007 | B1 |
7282033 | Urmey | Oct 2007 | B2 |
7299095 | Barlow et al. | Nov 2007 | B1 |
7363076 | Yun et al. | Apr 2008 | B2 |
7363089 | Vinup et al. | Apr 2008 | B2 |
7379776 | Chitre et al. | May 2008 | B1 |
7381441 | Leung et al. | Jun 2008 | B2 |
7383090 | O'Brien et al. | Jun 2008 | B2 |
7386350 | Vilims | Jun 2008 | B2 |
7421297 | Giftakis et al. | Sep 2008 | B2 |
7425142 | Putz | Sep 2008 | B1 |
7455666 | Purdy | Nov 2008 | B2 |
7463917 | Martinez | Dec 2008 | B2 |
7493159 | Hrdlicka et al. | Feb 2009 | B2 |
7499755 | Cross, Jr. | Mar 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7590454 | Garabedian et al. | Sep 2009 | B2 |
7613524 | Jordan | Nov 2009 | B2 |
7617003 | Caparso et al. | Nov 2009 | B2 |
7623919 | Goetz et al. | Nov 2009 | B2 |
7676273 | Goetz et al. | Mar 2010 | B2 |
7689284 | Imran et al. | Mar 2010 | B2 |
7702379 | Avinash et al. | Apr 2010 | B2 |
7769472 | Gerber | Aug 2010 | B2 |
7781806 | VanBuskirk et al. | Aug 2010 | B2 |
7810233 | Krulevitch et al. | Oct 2010 | B2 |
7810996 | Giphart et al. | Oct 2010 | B1 |
7831307 | Moffitt | Nov 2010 | B1 |
7844343 | Wahlstrand et al. | Nov 2010 | B2 |
7853330 | Bradley et al. | Dec 2010 | B2 |
7860568 | Deininger et al. | Dec 2010 | B2 |
7881806 | Horrigan et al. | Feb 2011 | B2 |
7957808 | Dawant et al. | Jun 2011 | B2 |
7996055 | Hauck et al. | Aug 2011 | B2 |
8010207 | Smits et al. | Aug 2011 | B2 |
8019439 | Kuzma et al. | Sep 2011 | B2 |
8036756 | Swoyer et al. | Oct 2011 | B2 |
8060207 | Wallace et al. | Nov 2011 | B2 |
8078280 | Sage | Dec 2011 | B2 |
8131357 | Bradley et al. | Mar 2012 | B2 |
8197494 | Jaggi et al. | Jun 2012 | B2 |
8224459 | Pianca et al. | Jul 2012 | B1 |
8255057 | Fang et al. | Aug 2012 | B2 |
8303502 | Washburn et al. | Nov 2012 | B2 |
8355791 | Moffitt | Jan 2013 | B2 |
8355797 | Caparso et al. | Jan 2013 | B2 |
8494652 | Cantlon et al. | Jul 2013 | B2 |
8548601 | Chinn et al. | Oct 2013 | B2 |
8634934 | Kokones et al. | Jan 2014 | B2 |
8676331 | Parker | Mar 2014 | B2 |
8682447 | Bradley | Mar 2014 | B2 |
8731671 | Rodby et al. | May 2014 | B2 |
8913804 | Blum et al. | Dec 2014 | B2 |
8965482 | Thacker et al. | Feb 2015 | B2 |
9002460 | Parker | Apr 2015 | B2 |
9345891 | Thacker et al. | May 2016 | B2 |
9358390 | Polefko et al. | Jun 2016 | B2 |
9403020 | Wingeier | Aug 2016 | B2 |
9433795 | Lui et al. | Sep 2016 | B2 |
9604059 | Parker | Mar 2017 | B2 |
10076665 | Parker et al. | Sep 2018 | B2 |
20010023368 | Black et al. | Sep 2001 | A1 |
20010025192 | Gerber et al. | Sep 2001 | A1 |
20010027336 | Gielen et al. | Oct 2001 | A1 |
20010053885 | Gielen et al. | Dec 2001 | A1 |
20020022872 | Gielen et al. | Feb 2002 | A1 |
20020052640 | Bigus et al. | May 2002 | A1 |
20020111661 | Cross et al. | Aug 2002 | A1 |
20020173718 | Frisch | Nov 2002 | A1 |
20020177887 | Krebs | Nov 2002 | A1 |
20030032997 | Pianca et al. | Feb 2003 | A1 |
20030055476 | Vinup et al. | Mar 2003 | A1 |
20030083697 | Baudino et al. | May 2003 | A1 |
20030083724 | Jog et al. | May 2003 | A1 |
20030097165 | Krulevitch et al. | May 2003 | A1 |
20030097166 | Krulevitch et al. | May 2003 | A1 |
20030114752 | Henderson et al. | Jun 2003 | A1 |
20030120150 | Govari | Jun 2003 | A1 |
20030136418 | Behm | Jul 2003 | A1 |
20030199949 | Pardo | Oct 2003 | A1 |
20030199951 | Pardo et al. | Oct 2003 | A1 |
20030199952 | Stolz et al. | Oct 2003 | A1 |
20030199953 | Stolz et al. | Oct 2003 | A1 |
20030199962 | Struble et al. | Oct 2003 | A1 |
20030208247 | Spinelli et al. | Nov 2003 | A1 |
20030229387 | Cross et al. | Dec 2003 | A1 |
20030233134 | Greenberg et al. | Dec 2003 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040015206 | Bishay et al. | Jan 2004 | A1 |
20040024439 | Riso | Feb 2004 | A1 |
20040024440 | Cole | Feb 2004 | A1 |
20040087877 | Besz et al. | May 2004 | A1 |
20040088033 | Smits et al. | May 2004 | A1 |
20040088034 | Smits et al. | May 2004 | A1 |
20040093053 | Gerber et al. | May 2004 | A1 |
20040097803 | Panescu | May 2004 | A1 |
20040111139 | McCreery | Jun 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040162601 | Smits | Aug 2004 | A1 |
20040176683 | Whitin et al. | Sep 2004 | A1 |
20040186528 | Ries et al. | Sep 2004 | A1 |
20040186543 | King et al. | Sep 2004 | A1 |
20040186544 | King | Sep 2004 | A1 |
20040215288 | Lee et al. | Oct 2004 | A1 |
20040215301 | Lokhoff et al. | Oct 2004 | A1 |
20040215305 | Sage | Oct 2004 | A1 |
20040215307 | Michels et al. | Oct 2004 | A1 |
20040243206 | Tadlock | Dec 2004 | A1 |
20050004638 | Cross | Jan 2005 | A1 |
20050004639 | Erickson | Jan 2005 | A1 |
20050015128 | Rezai et al. | Jan 2005 | A1 |
20050021119 | Sage et al. | Jan 2005 | A1 |
20050027325 | Lahti et al. | Feb 2005 | A1 |
20050027338 | Hill | Feb 2005 | A1 |
20050027339 | Schrom et al. | Feb 2005 | A1 |
20050027340 | Schrom et al. | Feb 2005 | A1 |
20050027341 | Schrom et al. | Feb 2005 | A1 |
20050033371 | Sommer et al. | Feb 2005 | A1 |
20050049486 | Urquhart et al. | Mar 2005 | A1 |
20050049663 | Harris et al. | Mar 2005 | A1 |
20050049664 | Harris et al. | Mar 2005 | A1 |
20050065588 | Zhao et al. | Mar 2005 | A1 |
20050070982 | Heruth et al. | Mar 2005 | A1 |
20050070987 | Erickson | Mar 2005 | A1 |
20050075684 | Phillips et al. | Apr 2005 | A1 |
20050075707 | Meadows et al. | Apr 2005 | A1 |
20050085870 | Goroszeniuk | Apr 2005 | A1 |
20050107859 | Daglow et al. | May 2005 | A1 |
20050107861 | Harris et al. | May 2005 | A1 |
20050113882 | Cameron et al. | May 2005 | A1 |
20050119713 | Whitehurst et al. | Jun 2005 | A1 |
20050131506 | Rezai et al. | Jun 2005 | A1 |
20050137667 | Omar-Pasha et al. | Jun 2005 | A1 |
20050137668 | Khan | Jun 2005 | A1 |
20050138791 | Black et al. | Jun 2005 | A1 |
20050138792 | Black et al. | Jun 2005 | A1 |
20050165465 | Pianca et al. | Jul 2005 | A1 |
20050171587 | Daglow et al. | Aug 2005 | A1 |
20050192655 | Black et al. | Sep 2005 | A1 |
20050203599 | Garabedian et al. | Sep 2005 | A1 |
20050209667 | Erickson et al. | Sep 2005 | A1 |
20050222642 | Przybyszewski et al. | Oct 2005 | A1 |
20050222657 | Wahlstrand et al. | Oct 2005 | A1 |
20050222658 | Hoegh et al. | Oct 2005 | A1 |
20050222659 | Olsen et al. | Oct 2005 | A1 |
20050228221 | Hirakawa | Oct 2005 | A1 |
20050246003 | Black et al. | Nov 2005 | A1 |
20050246004 | Cameron et al. | Nov 2005 | A1 |
20060004429 | Mrva et al. | Jan 2006 | A1 |
20060052765 | Pyles et al. | Mar 2006 | A1 |
20060074456 | Pyles et al. | Apr 2006 | A1 |
20060089692 | Cross et al. | Apr 2006 | A1 |
20060089695 | Bolea et al. | Apr 2006 | A1 |
20060089696 | Olsen et al. | Apr 2006 | A1 |
20060089697 | Cross et al. | Apr 2006 | A1 |
20060111768 | Wessman et al. | May 2006 | A1 |
20060127158 | Olson et al. | Jun 2006 | A1 |
20060168805 | Hegland et al. | Aug 2006 | A1 |
20060173262 | Hegland et al. | Aug 2006 | A1 |
20060200218 | Wahlstrand | Sep 2006 | A1 |
20060247747 | Olsen et al. | Nov 2006 | A1 |
20060247748 | Wahlstrand et al. | Nov 2006 | A1 |
20060247749 | Colvin | Nov 2006 | A1 |
20060253182 | King | Nov 2006 | A1 |
20060264122 | Aman et al. | Nov 2006 | A1 |
20060265024 | Goetz et al. | Nov 2006 | A1 |
20060265025 | Goetz et al. | Nov 2006 | A1 |
20060265037 | Kuzma | Nov 2006 | A1 |
20060271137 | Stanton-Hicks | Nov 2006 | A1 |
20070038052 | Swoyer et al. | Feb 2007 | A1 |
20070050004 | Swoyer et al. | Mar 2007 | A1 |
20070050005 | Lauro | Mar 2007 | A1 |
20070055332 | Swoyer | Mar 2007 | A1 |
20070100386 | Tronnes et al. | May 2007 | A1 |
20070100408 | Gerber | May 2007 | A1 |
20070106144 | Squeri | May 2007 | A1 |
20070106289 | O'Sullivan | May 2007 | A1 |
20070112398 | Stevenson et al. | May 2007 | A1 |
20070112404 | Mann et al. | May 2007 | A1 |
20070118198 | Prager | May 2007 | A1 |
20070149048 | O'Brien et al. | Jun 2007 | A1 |
20070150036 | Anderson | Jun 2007 | A1 |
20070191903 | Bruinstroop | Aug 2007 | A1 |
20070191904 | Libbus et al. | Aug 2007 | A1 |
20070203540 | Goetz et al. | Aug 2007 | A1 |
20070208394 | King et al. | Sep 2007 | A1 |
20070249901 | Ohline et al. | Oct 2007 | A1 |
20070260290 | Hara et al. | Nov 2007 | A1 |
20080039738 | Dinsmoor et al. | Feb 2008 | A1 |
20080058875 | Greenberg et al. | Mar 2008 | A1 |
20080097475 | Jaggi et al. | Apr 2008 | A1 |
20080125833 | Bradley et al. | May 2008 | A1 |
20080140087 | Barbagli | Jun 2008 | A1 |
20080140152 | Imran et al. | Jun 2008 | A1 |
20080183221 | Burdulis | Jul 2008 | A1 |
20080215118 | Goetz et al. | Sep 2008 | A1 |
20080234791 | Arle et al. | Sep 2008 | A1 |
20080262430 | Anderson et al. | Oct 2008 | A1 |
20080275467 | Liao et al. | Nov 2008 | A1 |
20080300651 | Gerber et al. | Dec 2008 | A1 |
20080319311 | Hamadeh | Dec 2008 | A1 |
20090024187 | Erickson et al. | Jan 2009 | A1 |
20090048638 | Rey et al. | Feb 2009 | A1 |
20090125060 | Rivard et al. | May 2009 | A1 |
20090198306 | Goetz et al. | Aug 2009 | A1 |
20090204173 | Fang | Aug 2009 | A1 |
20090204192 | Carlton et al. | Aug 2009 | A1 |
20090210029 | Tsui | Aug 2009 | A1 |
20090248118 | Bradley et al. | Oct 2009 | A1 |
20090270940 | Deininger et al. | Oct 2009 | A1 |
20100069736 | Finneran et al. | Mar 2010 | A1 |
20100094116 | Silverstein | Apr 2010 | A1 |
20100137944 | Zhu | Jun 2010 | A1 |
20100137955 | Milijasevic et al. | Jun 2010 | A1 |
20100152538 | Gleason | Jun 2010 | A1 |
20100204569 | Burnside et al. | Aug 2010 | A1 |
20100211135 | Caparso et al. | Aug 2010 | A1 |
20100222844 | Troosters et al. | Sep 2010 | A1 |
20100267265 | Dilmaghanian | Oct 2010 | A1 |
20100274312 | Alataris et al. | Oct 2010 | A1 |
20100274314 | Alataris et al. | Oct 2010 | A1 |
20100274315 | Alataris et al. | Oct 2010 | A1 |
20100274316 | Alataris et al. | Oct 2010 | A1 |
20100274336 | Nguyen-Stella et al. | Oct 2010 | A1 |
20100286551 | Harlev et al. | Nov 2010 | A1 |
20100298905 | Simon | Nov 2010 | A1 |
20100305631 | Bradley et al. | Dec 2010 | A1 |
20100324414 | Harlev et al. | Dec 2010 | A1 |
20100324570 | Rooney et al. | Dec 2010 | A1 |
20110009927 | Parker et al. | Jan 2011 | A1 |
20110031961 | Durand et al. | Feb 2011 | A1 |
20110046617 | Thompson et al. | Feb 2011 | A1 |
20110054304 | Markowitz | Mar 2011 | A1 |
20110054551 | Zhu et al. | Mar 2011 | A1 |
20110060386 | Woods et al. | Mar 2011 | A1 |
20110066407 | Butson et al. | Mar 2011 | A1 |
20110093051 | Davis | Apr 2011 | A1 |
20110106052 | Chiang et al. | May 2011 | A1 |
20110160568 | Seeley | Jun 2011 | A1 |
20110178573 | Nguyen-Stella et al. | Jul 2011 | A1 |
20110245903 | Schulte et al. | Oct 2011 | A1 |
20110307032 | Goetz et al. | Dec 2011 | A1 |
20120083709 | Parker et al. | Apr 2012 | A1 |
20120083856 | Thacker et al. | Apr 2012 | A1 |
20120083857 | Bradley | Apr 2012 | A1 |
20120173946 | Terry et al. | Jul 2012 | A1 |
20120232626 | Daglow | Sep 2012 | A1 |
20120232810 | Kaipio et al. | Sep 2012 | A1 |
20130066411 | Thacker et al. | Mar 2013 | A1 |
20130096642 | Wingeier | Apr 2013 | A1 |
20130116754 | Sharma et al. | May 2013 | A1 |
20130261697 | Parker | Oct 2013 | A1 |
20140303685 | Rosenberg et al. | Oct 2014 | A1 |
20150012077 | Parker et al. | Jan 2015 | A1 |
20160059006 | Doan et al. | Mar 2016 | A1 |
20160302827 | Chitre | Oct 2016 | A1 |
20160354609 | Parker et al. | Dec 2016 | A1 |
20160360993 | Thacker et al. | Dec 2016 | A1 |
20190217096 | Parker | Jul 2019 | A1 |
Number | Date | Country |
---|---|---|
101920065 | Dec 2010 | CN |
0158316 | Oct 1985 | EP |
WO-9003824 | Apr 1990 | WO |
WO-2009097224 | Aug 2009 | WO |
WO-2009129329 | Oct 2009 | WO |
WO-2011014570 | Feb 2011 | WO |
WO-2011143258 | Nov 2011 | WO |
Entry |
---|
International Search Report and Written Opinion for International Patent Application No. PCT/US11/53714, Applicant: Nevro Corporation, dated Aug. 10, 2012, 14 pages. |
Kulkarni et al., “A two-layered forward model of tissue for electrical; impedance tomography,” Physiol Meas., 30(6); pp. 1-24, Jun. 2009. |
Medtronic “N'Vision Cliniciam (8840) Programmer with Software (8870)—Restore and RestorePRIME Neurostimulation Systems for Pain,” 2006, 109 pages. |
Falowski et al. “Spinal Cord Stimulation: An Update,” Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, vol. 5, Jan. 2008, 14 pages. |
Shealy et al., “Electrical Inhibition of Pain: Experimental Evaluation,” Anesthesia and Analgesia, vol. 46, No. 3, May-Jun. 1967, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20190320936 A1 | Oct 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15148987 | May 2016 | US |
Child | 16287486 | US | |
Parent | 14598114 | Jan 2015 | US |
Child | 15148987 | US | |
Parent | 12895403 | Sep 2010 | US |
Child | 14598114 | US |